Skip to main content

Year in review · from our October 2026 register copy

NAFDAC registrations in 2025

By the approval dates our October 2026 copy of the Greenbook records, 1,249 products were approved onto the register in 2025 — 1,139 of them in Drugs. 99% of the class of 2025 is still active in our copy today.

By category

Month by month

Approvals are batched — quiet months and spikes are the register's own rhythm, not demand.

Jan
135
Feb
51
Mar
63
Apr
91
May
106
Jun
131
Jul
167
Aug
125
Sep
78
Oct
169
Nov
120
Dec
13

Who registered the most

  1. 1.First Vadis Pharmaceutical Industries— 20 approvals
  2. 2.Emzor Pharmaceutical Industries— 17 approvals
  3. 3.Getz Pharma Nigeria— 16 approvals
  4. 4.Swiss Pharma Nigeria— 16 approvals
  5. 5.Fensyl MHP Consulting— 15 approvals
  6. 6.Avro Pharma— 13 approvals
  7. 7.Global Young Pharma— 13 approvals
  8. 8.Priya Pharmaceutical— 13 approvals
  9. 9.AnnyGod Pharmaceutical— 12 approvals
  10. 10.MC Foris Pharmaceuticals— 12 approvals

Where the year's medicines were made

Factory countries recorded on 1,139 of the year's 1,139 drug approvals.

Month-to-month changes — new listings, renewals, lapses — live on the NAFDAC Registry Watch, updated with every register refresh.

Other years

Counted from the approval dates in our dated copy of the public NAFDAC Greenbook. The register backfills approval entries long after the fact, so a year's count can still grow after it ends — which is also why the current year has no page until it completes. Registration counts are not market share or sales.